These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 31340883)

  • 1. Molecular profiling and molecular classification of endometrioid ovarian carcinomas.
    Cybulska P; Paula ADC; Tseng J; Leitao MM; Bashashati A; Huntsman DG; Nazeran TM; Aghajanian C; Abu-Rustum NR; DeLair DF; Shah SP; Weigelt B
    Gynecol Oncol; 2019 Sep; 154(3):516-523. PubMed ID: 31340883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Massively Parallel Sequencing-Based Clonality Analysis of Synchronous Endometrioid Endometrial and Ovarian Carcinomas.
    Schultheis AM; Ng CK; De Filippo MR; Piscuoglio S; Macedo GS; Gatius S; Perez Mies B; Soslow RA; Lim RS; Viale A; Huberman KH; Palacios JC; Reis-Filho JS; Matias-Guiu X; Weigelt B
    J Natl Cancer Inst; 2016 Jun; 108(6):djv427. PubMed ID: 26832770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TP53 mutations are common in all subtypes of epithelial ovarian cancer and occur concomitantly with KRAS mutations in the mucinous type.
    Rechsteiner M; Zimmermann AK; Wild PJ; Caduff R; von Teichman A; Fink D; Moch H; Noske A
    Exp Mol Pathol; 2013 Oct; 95(2):235-41. PubMed ID: 23965232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PIKing the type and pattern of PI3K pathway mutations in endometrioid endometrial carcinomas.
    Marchiò C; De Filippo MR; Ng CK; Piscuoglio S; Soslow RA; Reis-Filho JS; Weigelt B
    Gynecol Oncol; 2015 May; 137(2):321-8. PubMed ID: 25701704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of mutation profiles to refine the classification of endometrial carcinomas.
    McConechy MK; Ding J; Cheang MC; Wiegand K; Senz J; Tone A; Yang W; Prentice L; Tse K; Zeng T; McDonald H; Schmidt AP; Mutch DG; McAlpine JN; Hirst M; Shah SP; Lee CH; Goodfellow PJ; Gilks CB; Huntsman DG
    J Pathol; 2012 Sep; 228(1):20-30. PubMed ID: 22653804
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma.
    Madore J; Ren F; Filali-Mouhim A; Sanchez L; Köbel M; Tonin PN; Huntsman D; Provencher DM; Mes-Masson AM
    J Pathol; 2010 Feb; 220(3):392-400. PubMed ID: 19967725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An integrated molecular profile of endometrioid ovarian cancer.
    Pierson WE; Peters PN; Chang MT; Chen LM; Quigley DA; Ashworth A; Chapman JS
    Gynecol Oncol; 2020 Apr; 157(1):55-61. PubMed ID: 32139151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutation profile and clinical outcome of mixed endometrioid-serous endometrial carcinomas are different from that of pure endometrioid or serous carcinomas.
    Coenegrachts L; Garcia-Dios DA; Depreeuw J; Santacana M; Gatius S; Zikan M; Moerman P; Verbist L; Lambrechts D; Matias-Guiu X; Amant F
    Virchows Arch; 2015 Apr; 466(4):415-22. PubMed ID: 25677978
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TP53 Mutational Spectrum in Endometrioid and Serous Endometrial Cancers.
    Schultheis AM; Martelotto LG; De Filippo MR; Piscuglio S; Ng CK; Hussein YR; Reis-Filho JS; Soslow RA; Weigelt B
    Int J Gynecol Pathol; 2016 Jul; 35(4):289-300. PubMed ID: 26556035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations.
    Hussein YR; Weigelt B; Levine DA; Schoolmeester JK; Dao LN; Balzer BL; Liles G; Karlan B; Köbel M; Lee CH; Soslow RA
    Mod Pathol; 2015 Apr; 28(4):505-14. PubMed ID: 25394778
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Heterogeneity of Endometrioid Ovarian Carcinoma: An Analysis of 166 Cases Using the Endometrial Cancer Subrogate Molecular Classification.
    Leskela S; Romero I; Rosa-Rosa JM; Caniego-Casas T; Cristobal E; Pérez-Mies B; Gutierrez-Pecharroman A; Santón A; Ojeda B; López-Reig R; Palacios-Berraquero ML; Andrada E; Montes S; Pastor F; Gomez MC; López-Guerrero JA; Poveda A; Palacios J
    Am J Surg Pathol; 2020 Jul; 44(7):982-990. PubMed ID: 32384322
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The genetic landscape of endometrial clear cell carcinomas.
    DeLair DF; Burke KA; Selenica P; Lim RS; Scott SN; Middha S; Mohanty AS; Cheng DT; Berger MF; Soslow RA; Weigelt B
    J Pathol; 2017 Oct; 243(2):230-241. PubMed ID: 28718916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Massively parallel sequencing analysis of mucinous ovarian carcinomas: genomic profiling and differential diagnoses.
    Mueller JJ; Schlappe BA; Kumar R; Olvera N; Dao F; Abu-Rustum N; Aghajanian C; DeLair D; Hussein YR; Soslow RA; Levine DA; Weigelt B
    Gynecol Oncol; 2018 Jul; 150(1):127-135. PubMed ID: 29793804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, PTEN expression, and ARID1A expression.
    Huang HN; Lin MC; Tseng LH; Chiang YC; Lin LI; Lin YF; Huang HY; Kuo KT
    Histopathology; 2015 Mar; 66(4):517-28. PubMed ID: 25195947
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenetic pathways in ovarian endometrioid adenocarcinoma: a molecular study of 29 cases.
    Geyer JT; López-García MA; Sánchez-Estevez C; Sarrió D; Moreno-Bueno G; Franceschetti I; Palacios J; Oliva E
    Am J Surg Pathol; 2009 Aug; 33(8):1157-63. PubMed ID: 19542870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mixed endometrial carcinomas with a "low-grade serous"-like component: a clinicopathologic, immunohistochemical, and molecular genetic study.
    Espinosa I; D'Angelo E; Corominas M; Gonzalez A; Prat J
    Hum Pathol; 2018 Jan; 71():65-73. PubMed ID: 29079180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.
    Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ
    Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epithelial ovarian cancer: rationale for changing the one-fits-all standard treatment regimen to subtype-specific treatment.
    Despierre E; Yesilyurt BT; Lambrechts S; Johnson N; Verheijen R; van der Burg M; Casado A; Rustin G; Berns E; Leunen K; Amant F; Moerman P; Lambrechts D; Vergote I;
    Int J Gynecol Cancer; 2014 Mar; 24(3):468-77. PubMed ID: 24557434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification and clinical significance of somatic oncogenic mutations in epithelial ovarian cancer.
    Watanabe T; Nanamiya H; Endo Y; Kojima M; Nomura S; Furukawa S; Soeda S; Tamura H; Ryufuku M; Tanaka D; Isogai T; Imai JI; Watanabe S; Fujimori K
    J Ovarian Res; 2021 Oct; 14(1):129. PubMed ID: 34615547
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic alterations and their therapeutic implications in epithelial ovarian cancer.
    Lapke N; Chen CH; Chang TC; Chao A; Lu YJ; Lai CH; Tan KT; Chen HC; Lu HY; Chen SJ
    BMC Cancer; 2021 May; 21(1):499. PubMed ID: 33947352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.